In non–small‐cell lung carcinoma (NSCLC), NF‐κB activation contributes to resistance against tyrosine kinase inhibitors, underscoring its critical role in cancer survival and positioning it as a potential therapeutic target.206. The gene discussed is NFKB1; the disease is cancer.